Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Oncology Research|April 3, 2026
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and DiabetesAndrea Dalbeni, Marco Vicardi, Leonardo A Natola, et al.
The Lancet. Oncology|May 31, 2022
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
BMC Cancer|April 8, 2024
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY studyMonica Niger, Federico Nichetti, Lorenzo Fornaro, et al.
BMC Cancer|March 30, 2019
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Monica Niger, Federica Morano, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 29, 2025
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON StudyCarolina Sciortino, Federico Nichetti, Francesca Bergamo, et al.
Nature Medicine|September 30, 2025
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trialPaolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2025
The Impact of Concordance Between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the Rome TrialAndrea Botticelli, Chiara Cremolini, Simone Scagnoli, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
Pageof 9